DB04963InvestigationalVaccines
rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 1.Curator reviewed
- Also known as
- Recombinant human GAD65 · Recombinant human glutamate decarboxylase 2 · Recombinant human glutamic acid decarboxylase
- Code names
- rhGAD65
Resolves to
Compound
What you can answer from here — as of April 02, 2025
Which companies are running trials of rhGAD65, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account